Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2023

STOCK-BASED COMPENSATION

Summary of amounts charged to expense for stock-based compensation related to employee and director stock option grants


		Three Months Ended
		March 31,
		2023			2022

Employee and director stock option grants:
Research and development		$	66,195		$	41,928
General and administrative			342,011			261,877
Total stock-based compensation		$	408,206		$	303,805

Summary of stock options activity


							Weighted
		Number of					Average
		Shares Issuable					Remaining
		Upon Exercise		Weighted			Contracted		Aggregate
		of Outstanding		Average			Term in		Intrinsic
		Options		Exercise Price			Years		Value
Outstanding at December 31, 2022		746,257		$	13.48				$	—
Granted		732,500		$	1.68
Forfeited		(1)		$	14,800
Outstanding at March 31, 2023		1,478,756		$	7.59		9.06		$	—

Exercisable March 31, 2023		370,959		$	20.06		7.74		$	—
Unvested, March 31, 2023		1,107,797		$	3.42		9.51		$	—